Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153006 | 0.90 | ALDH1A1 (0.57) | CYP4F2CYP4A11L3MBTL1KDM4EMEN1 | |
| SCHEMBL6152322 | 0.84 | LTA4H (0.51) | L3MBTL1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6153126 | 0.82 | L3MBTL1 (0.43) | L3MBTL1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL69660 | 0.77 | CYP4F2 (0.86) | CYP4F2CYP4A11KDM4EALDH1A1GAA | |
| SCHEMBL6153020 | 0.77 | CDYL (0.59) | CYP4F2CYP4A11KDM4EALDH1A1GAA | |
| SCHEMBL28008696 | 0.74 | CYP4F2 (0.81) | CYP4F2CYP4A11KDM4EALDH1A1GAA | |
| SCHEMBL6152429 | 0.73 | ALDH1A1 (0.53) | L3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL6153686 | 0.73 | ALDH1A1 (0.47) | L3MBTL1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6152351 | 0.72 | L3MBTL1 (0.41) | L3MBTL1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL22098182 | 0.72 | CYP4F2 (1.00) | CYP4F2CYP4A11KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CYP4F2 1994/4885CYP4A11 1123/4885L3MBTL1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.